<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Evogene — News on 6ix</title>
<link>https://6ix.com/company/evogene</link>
<description>Latest news and press releases for Evogene on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/evogene" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835652178dffbe2df0eff2f.webp</url>
<title>Evogene</title>
<link>https://6ix.com/company/evogene</link>
</image>
<item>
<title>Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification</title>
<link>https://6ix.com/company/evogene/news/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-reports-receipt-of-nasdaq-minimum-bid-price-notification</guid>
<pubDate>Thu, 02 Apr 2026 20:01:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1</description>
</item>
<item>
<title>Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock</title>
<link>https://6ix.com/company/evogene/news/casterra-announces-successful-commercial-field-trials-in-brazil-positioning-castor-oil-as-a-promising-candidate-for-economically-viable-biofuel-feedstock</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/casterra-announces-successful-commercial-field-trials-in-brazil-positioning-castor-oil-as-a-promising-candidate-for-economically-viable-biofuel-feedstock</guid>
<pubDate>Tue, 31 Mar 2026 12:00:00 GMT</pubDate>
<description>Casterra Ag Ltd. ("Casterra"), a developer of high-yield castor seed varieties and integrated castor farming solutions, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced successful commercial field trials in Brazil, highlighting castor oil as a compelling candidate for economically viable biofuel production. At present, castor oil is widely recognized as a high-value, sustainable feedstock for bio-based industries (lubricants, surface coatings, cosmetics, pharmaceutic</description>
</item>
<item>
<title>Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026</title>
<link>https://6ix.com/company/evogene/news/evogene-to-present-its-pharma-discovery-achievements-at-bio-europe-spring-2026</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-to-present-its-pharma-discovery-achievements-at-bio-europe-spring-2026</guid>
<pubDate>Mon, 09 Mar 2026 13:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon. Attending the conference on behalf of Evogene will be Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development.</description>
</item>
<item>
<title>Evogene Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/evogene/news/evogene-reports-fourth-quarter-and-full-year-2025-financial-results-6</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-reports-fourth-quarter-and-full-year-2025-financial-results-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>Conference call and webcast: today, March 05, 2026, 9:00 AM ETREHOVOT, Israel, March 5, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a</description>
</item>
<item>
<title>Evogene Releases CEO Letter to Shareholders</title>
<link>https://6ix.com/company/evogene/news/evogene-releases-ceo-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-releases-ceo-letter-to-shareholders</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Updating on Strategic Progress and OutlookREHOVOT, Israel, Feb. 25, 2026 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational</description>
</item>
<item>
<title>Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release</title>
<link>https://6ix.com/company/evogene/news/evogene-schedules-fourth-quarter-and-full-year-2025-financial-results-release</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-schedules-fourth-quarter-and-full-year-2025-financial-results-release</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>Zoom conference call scheduled for March 5, 2026, 9:00 AM ET REHOVOT, Israel, Feb. 19, 2026 /PRNewswire/ -- Evogene Ltd . (NASDAQ: EVGN) (TASE: EVGN), a</description>
</item>
<item>
<title>Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics</title>
<link>https://6ix.com/company/evogene/news/evogene-queensland-university-technology-qut-130000456</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-queensland-university-technology-qut-130000456</guid>
<pubDate>Tue, 17 Feb 2026 13:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries today announced a collaboration with the pioneering research group of Dr. Mark Adams, a leading cancer genomics expert in the School of Biomedical Sciences and Faculty of Health at the Queensland University of Technology (QUT), Australia. This partnership aims to accelerate the discovery and optimization</description>
</item>
<item>
<title>Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases</title>
<link>https://6ix.com/company/evogene/news/evogene-systasy-lmu-university-hospital-130000032</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-systasy-lmu-university-hospital-130000032</guid>
<pubDate>Wed, 11 Feb 2026 13:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, Systasy Bioscience GmbH, a biotechnology company leveraging proprietary DNA barcoding technology for hyper-multiplexed pathway profiling in patient-derived iPSC models to accelerate drug discovery for complex disorders, and LMU University Hospital Munich, today announced a collaboration aiming to accele</description>
</item>
<item>
<title>Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds</title>
<link>https://6ix.com/company/evogene/news/evogene-announces-warrant-inducement-transaction-182000898</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-announces-warrant-inducement-transaction-182000898</guid>
<pubDate>Tue, 10 Feb 2026 18:20:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) ("Evogene" or the "Company"), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its entry into a warrant inducement agreement with an existing institutional investor of the Company for the immediate exercise of the August 2024 Series A ordinary warrants to purchase up to 1,692,308 ordinary shares (the "Series A Warrants"), and August 20</description>
</item>
<item>
<title>Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™</title>
<link>https://6ix.com/company/evogene/news/evogene-announces-expanded-collaboration-google-130000022</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-announces-expanded-collaboration-google-130000022</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a computational chemistry company focused on AI-driven small-molecule design for the pharmaceutical and agricultural industries, today announced an expanded phase of its collaboration with Google Cloud. Under this new phase, the collaboration will focus on developing and integrating advanced AI Agents into Evogene's ChemPass AI™ platform, its proprietary engine for small-molecule discovery and optimization, using Google Cloud's Vertex AI platform. The go</description>
</item>
<item>
<title>Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board</title>
<link>https://6ix.com/company/evogene/news/evogene-appoints-prof-john-irwin-130000947</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-appoints-prof-john-irwin-130000947</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational chemistry company focused on the AI-driven discovery and design of novel small molecules for the pharmaceutical and agricultural industries, today announced the appointment of Prof. John J. Irwin of the University of California, San Francisco (UCSF), and Prof. Dan T. Major of Bar-Ilan University (BIU) to its scientific advisory board (SAB).</description>
</item>
<item>
<title>Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer</title>
<link>https://6ix.com/company/evogene/news/evogene-shanghai-lishan-biopharmaceuticals-co-030000602</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-shanghai-lishan-biopharmaceuticals-co-030000602</guid>
<pubDate>Thu, 05 Feb 2026 03:00:00 GMT</pubDate>
<description>BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical resultsREHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene Ltd. (Nasdaq/TASE: EVGN) ("Evogene"), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, and Shanghai Lishan Biopharmaceuticals Co., Ltd. ("Lishan Biotech"), a China-based clinical-s</description>
</item>
<item>
<title>Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders</title>
<link>https://6ix.com/company/evogene/news/evogene-unravel-biosciences-announce-collaboration-120000298</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-unravel-biosciences-announce-collaboration-120000298</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine™ platform. This partnership aims to accelerate the discovery and optimization of a first-in-class small-mol</description>
</item>
<item>
<title>Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development</title>
<link>https://6ix.com/company/evogene/news/evogene-announces-appointment-dr-olga-120000765</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-announces-appointment-dr-olga-120000765</guid>
<pubDate>Tue, 30 Dec 2025 12:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, is pleased to announce the appointment of Dr. Olga Nissan as its Vice President of Business Development, effective as of January 1, 2026.</description>
</item>
<item>
<title>Evogene Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/evogene/news/evogene-reports-third-quarter-2025-120000570</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-reports-third-quarter-2025-120000570</guid>
<pubDate>Thu, 20 Nov 2025 12:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming</title>
<link>https://6ix.com/company/evogene/news/casterra-and-fantini-partner-to-advance-agricultural-mechanization-for-scalable-commercial-castor-farming</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/casterra-and-fantini-partner-to-advance-agricultural-mechanization-for-scalable-commercial-castor-farming</guid>
<pubDate>Tue, 11 Nov 2025 12:00:00 GMT</pubDate>
<description>Casterra Ag Ltd. ("Casterra"), an Israeli developer of high-yield castor seed varieties and integrated castor farming solutions — and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), and Fantini Italia S.R.L. ("Fantini"), a leading Italian developer and manufacturer of agricultural harvesting equipment, today announced a strategic collaboration for large-scale, commercial castor cultivation through advanced mechanization technologies.</description>
</item>
<item>
<title>Evogene Schedules Third Quarter 2025 Financial Results Release</title>
<link>https://6ix.com/company/evogene/news/evogene-schedules-third-quarter-2025-140000084</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-schedules-third-quarter-2025-140000084</guid>
<pubDate>Thu, 06 Nov 2025 14:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the third quarter of 2025, on Thursday, November 20, 2025.</description>
</item>
<item>
<title>Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York</title>
<link>https://6ix.com/company/evogene/news/evogene-present-h-c-wainwright-110000983</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-present-h-c-wainwright-110000983</guid>
<pubDate>Thu, 28 Aug 2025 11:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company, today announced that Ofer Haviv, Evogene's President and CEO, will present at the H.C. Wainwright 27th Annual Global Investment Conference, 2025, taking place in New York, from September 8-10, 2025.</description>
</item>
<item>
<title>Evogene Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/evogene/news/evogene-reports-second-quarter-2025-110000858</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-reports-second-quarter-2025-110000858</guid>
<pubDate>Tue, 19 Aug 2025 11:00:00 GMT</pubDate>
<description>Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology and chemistry company aiming to revolutionize the development of life-science-based products, today announced its financial results for the second quarter ended June 30, 2025.</description>
</item>
<item>
<title>Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases</title>
<link>https://6ix.com/company/evogene/news/evogene-professor-ehud-gazit-tel-110000598</link>
<guid isPermaLink="true">https://6ix.com/company/evogene/news/evogene-professor-ehud-gazit-tel-110000598</guid>
<pubDate>Tue, 12 Aug 2025 11:00:00 GMT</pubDate>
<description>Evogene Ltd. (Nasdaq, TASE: EVGN), a leading computational biology and chemistry company, today announced a scientific collaboration with the pioneering research group of Professor Ehud Gazit from Tel Aviv University, a world leader in the field of molecular self-assembly. This collaboration agreement was facilitated by Ramot, Tel Aviv University's tech transfer company. This partnership aims to accelerate the discovery and optimization of novel small molecules as potential drug candidates for a</description>
</item>
</channel>
</rss>